Revlimid

Treatment for Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma

FDA and Celgene Revlimid Briefing Documents for Advisory Committee Meeting Available Online

WASHINGTON, September 13, 2005 -- Celgene Corporation announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the ODAC meeting scheduled to review the Revlimid (lenalidomide) New Drug Application (NDA) seeking approval for Revlimid for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
The ODAC meeting is scheduled from 8:00 a.m. EDT to 12:30 p.m. EDT on Wednesday, September 14, 2005. The NDA for Revlimid is under FDA priority review with a PDUFA date of October 7, 2005.

Source: Celgene Corporation

Posted: September 2005

Related Articles

Revlimid (lenalidomide) FDA Approval History

View comments

Hide
(web4)